×
News Home

Is Crispr Therapeutics AG (CRSP) Stock About to Get Hot Monday?

Monday, August 02, 2021 01:18 PM | InvestorsObserver Analysts
Is Crispr Therapeutics AG (CRSP) Stock About to Get Hot Monday?

Crispr Therapeutics AG (CRSP) stock is up 3.11% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Crispr Therapeutics AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $122.93 as of 1:08 PM on Monday, Aug 2, an increase of $1.91, or 1.58% from the previous closing price of $121.02. The stock has traded between $119.83 and $123.38 so far today. Volume today is below average. So far 601,088 shares have traded compared to average volume of 1,487,130 shares.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need. Click Here to get the full Stock Report for Crispr Therapeutics AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App